Actively Recruiting
Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma
Led by University of California, San Francisco · Updated on 2026-04-15
74
Participants Needed
8
Research Sites
309 weeks
Total Duration
On this page
Sponsors
U
University of California, San Francisco
Lead Sponsor
W
Washington University School of Medicine
Collaborating Sponsor
AI-Summary
What this Trial Is About
The current study will use a new treatment approach based on the molecular characteristics of each participant's tumor. The study will test the feasibility in the pilot phase of performing real-time drug screening on tissue taken during surgery in patients with relapsed medulloblastoma or ependymoma and of having a specialized tumor board assign a treatment plan based on the results of this screening and genomic sequencing. The aim of this trial is to allow every child and young adult with relapsed medulloblastoma and ependymoma to receive the most effective and least toxic therapies currently available and will pave the way for improved understanding and treatment of these tumors in the future. Moreover, if successful, it could serve as a paradigm for personalized medicine programs for other types of cancer.
CONDITIONS
Official Title
Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants must have recurrent medulloblastoma or ependymoma confirmed by pathology and be experiencing their first or second relapse.
- Participants must have disease accessible for surgery or biopsy with enough tissue expected for study.
- Participants must have received at least one prior therapy at initial diagnosis.
- Participants must have fully recovered from acute side effects of prior chemotherapy, immunotherapy, or radiotherapy before entering the study.
- Participants must have had the last chemotherapy or biologic agent at least 7 days before registration.
- Participants who received monoclonal antibody treatments must have had their last dose more than 21 days before registration.
- Participants must have had the last fraction of local or craniospinal irradiation at least 12 weeks before registration.
- Participants must be between 12 months and 39 years old.
- Karnofsky score of 50 or higher for those over 16 years old, Lansky score of 50 or higher for 16 years or younger.
- Participants on corticosteroids must be on a stable or decreasing dose for at least one week before registration.
- Adequate bone marrow, kidney, and liver function as defined by specific laboratory values within 7 days before registration.
- Women of childbearing potential and men must agree to use effective contraception during and for 4 months after therapy.
- Participants with well-controlled seizure disorders may enroll.
- Participants must enroll in the PNOC COMP study if it is open at the enrolling institution.
- Participants or their legal guardians must be able to understand and sign informed consent or assent.
You will not qualify if you...
- Participants who had chemotherapy or radiotherapy within 3 weeks prior to study entry (6 weeks for nitrosoureas or mitomycin C) or who have not recovered from previous treatment side effects.
- Participants receiving other investigational drugs.
- Participants who completed biologic or small molecule agent therapy less than 7 days before enrollment or during adverse event risk periods.
- Participants currently receiving any anti-cancer therapy other than steroids.
- Participants with uncontrolled illness or active infections.
- Women who are pregnant or breastfeeding; a negative pregnancy test is required before starting therapy.
- Participants must not receive tumor-directed therapy after enrollment except surgery or biopsy.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 8 locations
1
Children's Hospital of Los Angeles
Los Angeles, California, United States, 90027
Actively Recruiting
2
Rady Children's Hospital
San Diego, California, United States, 92123
Actively Recruiting
3
University of California, San Francisco
San Francisco, California, United States, 94143
Actively Recruiting
4
Children's National Hospital
Washington D.C., District of Columbia, United States, 20010
Actively Recruiting
5
St. Louis Children's Hospital / Washington University in St. Louis
St Louis, Missouri, United States, 63130
Actively Recruiting
6
New York University
New York, New York, United States, 10016
Actively Recruiting
7
Columbia University Medical Center
New York, New York, United States, 10032
Actively Recruiting
8
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
Research Team
P
PNOC Operation Office
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
OTHER
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here